Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Everything is a let down with what every ones posts. I hope it does go up tired of listening to people say it'll be here and here im guilty of this to. So does any one Know when it will air at least?
adnit keeps creeping down.
I know what you mean. You think in December itll go up to that mark? .02?
I dunno thats what I was wondering cause everyone is saying its coming soon
I thought it was supposed to go up today?
yeah seems very strong nice bid and ask
WHAT IS GOING ON I'M FREAKING OUT.lol why is the BID .42 and the ask 2.oo NOOOOOOOOO
How do you figure if you don't mind me asking? Why would they take it down?
what you mean coming around?
Yeha looks like new high today so see what happens maybe 1.20's by end of week?
yeah they made the infemercial this month and are going to release it next month
Some time in december good time to get in thats for sure prolly in likes 2 to 3 weeks it will be out!
yet were down again this thing needs to air like last week.lol
Lol True True!! When Are they supposed to start drilling?
Definitely 2.00 by end of December then things start to get really interesting!
Falling like a brock today whats up with that?
Read This Our Drug Is mUch Safer And Has A Higher Chance of LIving.
WARNING
SERIOUS INFUSION REACTIONS, PROLONGED AND SEVERE CYTOPENIAS, and SEVERE CUTANEOUS AND MUCOCUTANEOUS REACTIONS
Serious Infusion Reactions: Deaths have occurred within 24 hours of rituximab infusion, an essential component of the Zevalin therapeutic regimen. These fatalities were associated with hypoxia, pulmonary infiltrates, acute respiratory distress syndrome, myocardial infarction, ventricular fibrillation, or cardiogenic shock. Most (80%) fatalities
occurred with the first rituximab infusion [see WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS]. Discontinue rituximab, In-111 Zevalin, and Y-90 Zevalin infusions in patients who develop severe infusion reactions.
Prolonged and Severe Cytopenias: Y-90 Zevalin administration results in severe and prolonged cytopenias in most patients. Do not administer the Zevalin therapeutic regimen to patients with = 25% lymphoma marrow involvement and/or impaired bone marrow reserve [see WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS].
Severe Cutaneous and Mucocutaneous Reactions: Severe cutaneous and mucocutaneous reactions, some fatal, can occur with the Zevalin therapeutic regimen. Discontinue rituximab, In-111 Zevalin, and Y-90 Zevalin infusions in patients experiencing severe cutaneous or mucocutaneous reactions [see WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS].
Dosing: The dose of Y-90 Zevalin should not exceed 32.0 mCi (1184 MBq). Do not administer Y-90 Zevalin to patients with altered biodistribution as determined by imaging with In-111 Zevalin [see DOSAGE AND ADMINISTRATION].
Ok so it looks like we could hit 10 dollars as a maximum
I could understand that but why not .10?
Studies Scheduled for 2010 Could Indicate as
Much as $50.61 Worth of Gold for Each 75-Cent
Share of Ironwood Gold Stock! On a report that we have all seen shows how much it'll go up. http://irogstockreport.com/
Fallow address to see the chart!!!
http://finance.yahoo.com/echarts?s=HGSI#symbol=HGSI;range=6m
I figure were fallowing the same path that they did if you know what I mean? Were just a few months behind!!!
EVERYONE READ!!!!!!!!!!! LOOK AT HGSI history for the last month of when they released and before it was released the build up for it it!!!! $5 thats kind of cutting it short by far because when HGSI released there Lupus drug the next day over night it went up 6 dollars a share alone then the next day up 3 more dollars and the last day after that 1 more dollar so it went up at least ten dollars from 18 to 28 lol. Don't sell yourself short. Their are already Lupus drugs
on the market and NONE I'M TELLING YOU NONE for Non Hutchinson Lymphoma..... There is no market for this drug thats why its so huge.
So this week is a big week? Why? they'll release information then by end of December? Is that the time frame were looking at?
hers the thing though after the huge rise if its true you think it'll go down after? Idle a bit then go up more? Or go up from there?
$5 thats kind of cutting it short by far because when HGSI released there Lupus drug the next day over night it went up 6 dollars a share alone then the next day up 3 more dollars and the last day after that 1 more dollar so it went up at least ten dollars from 18 to 28 lol. Don't sell yourself short. Their are already Lupus drugs on the market and NONE I'M TELLING YOU NONE for Non Hutchinson Lymphoma..... There is no market for this drug thats why its so huge.
I know what you are saying im saying by the time they do that it'll be up to were I need to sell it. Like .05 or .10
Again old information but shows who invented the Bulb and which company he works for!!LOL
NEW YORK, April 3, 2009 (GLOBE NEWSWIRE) -- Zevotek, Inc. (Pink Sheets:ZVTK) is
pleased to announce the addition of Chang Hun Kim who will act as the company's
comptroller on a consultant basis. He was brought to the company's attention by
Mr. Jason Ryu, the inventor of the company's product.
Mr. Kim has been an AICPA member since August of 2000. Mr. Chang Hun Kim is a
graduate of Columbia University with a BS in 1988 and a MS completed in May
1989. He passed all 4 parts of the CPA exam in his first seating and was brought
to the attention of the company via Mr. Ryu.
Jason Ryu, the inventor of the ionic bulb, has been working diligently on the
sales aspect of the business and, in anticipation of contracts being completed,
felt this addition was much needed to ensure proper measures of oversight.
Mr. Ryu, having a long standing business relationship with Mr. Kim, has been
able to obtain his services at no cost to the company at this current time but
has agreed as the contracts are completed that Mr. Kim will be fairly
compensated.
About the Company:
Zevotek, Inc. plans to market and sell independently a range of distinct and
independent lines of home care and household products. In May 2007, the company
entered into a license agreement to sell an energy saving compact fluorescent
light bulb named the Ionic Bulb. The company plans to market the Ionic Bulb
through TV infomercials, catalogs, magazines and major U.S. retail and specialty
stores and the website www.zevo-tek.com and www.ionic-bulb.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995: Forward-looking statements in this release with respect to the Zevotek,
Inc.'s business, financial condition and results of operations, as well as
matters of timing and the prospective terms of the transaction described are
subject to risks and uncertainties that could cause actual results to differ
materially from those expressed in the forward-looking statements, including,
but not limited to, certain delays beyond Diet Coffee, Inc.'s control with
respect to market acceptance of their products, whether financing will be
available, the plans for Zevotek, Inc. to market and sell home care and other
household products as well as certain other risk factors which are and may be
detailed from time to time in Zevotek, Inc.'s filings with the Securities and
Exchange Commission.
This press release contains forward-looking statements. The words or phrases
"may," "intends," "expects," "estimate," "indicate," "plans," "anticipates,"
"could," "if," "will," "should" or similar expressions are intended to identify
"forward-looking statements." Actual results could differ materially from those
projected in forward-looking statements as a result of a number of risks and
uncertainties. Statements made herein are as of the date of this press release
and should not be relied upon as of any subsequent date. Zevotek, Inc. cautions
readers not to place undue reliance on such statements. Unless otherwise
required by applicable law, Zevotek, Inc. does not undertake, and Zevotek, Inc.
specifically disclaims any obligation to update any forward- looking statements
to reflect occurrences, developments, unanticipated events or circumstances
after the date of such statement.
Some Old Information but usefull on who has sole rights!!!
Zevotek Completes Deal for Major European Distribution Deal
On Wednesday April 29, 2009, 4:05 pm EDT
NEW YORK, April 29, 2009 (GLOBE NEWSWIRE) — Zevotek, Inc., (Other OTC:ZVTK.PK - News) is pleased to announce the completion of an overseas marketing and sales agreement. The sales agreement shall cover the territories of Germany, Austria, Switzerland, Slovakia, Hungry, Liechtenstein, Romania, Poland and the Czech Republic.
This marks a major venture into the European market for Zevotek. With an infomercial being broadcast into multiple countries and put into several different languages it has more depth then previous given to our products then in earlier sales deals. With their vast experience in the As Seen on TV market we felt this was the best opportunity to gain market share at this juncture.
The agreement calls for 60,000 bulbs over a 12-month period as the foundation of the marketing agreement. As needed, our European partner, in this deal can increase their orders to meet demand. The number of bulbs this deal calls for is only a starting point as we feel that the company Zevotek has chosen to work with, has a strong track record, and will be able to help us gain a foothold in the increasing market of energy efficient lighting. Discussions on the nightlight product were tabled at this time as they have prepared only the standard bulbs infomercial.
Wow well I feel better that the report on Americas youth cant join the military up to 75% from ages 17 to 24 lol cause there to dumb or fat!!!!!!LOL Any ways Will see thats all we can do!
So how big will it be it airs like December in the beginning so you figure there will some reports like a week after or two unless they suck.lol What do you think I know you said .05 when will that be? I know its just a prediction not for real just curious!!!
FAIL!!!!!!!lol sorry bout that I wish we would start seeing more action now.lol I bet good month in December and January.
no I don't im poor man im in the military rarely get time to do anything always on stand by or deployed I work at first communications squadron.lol everyone's like do research if I had time I would I can only browse really.lol thank you for help. Really why .05 or dime by February?
I figure when they go public even that it will go up with the infomercial with no sales.lol am I wrong?
even though they don't a patent when they bought there license it went up to .015 so how do you explain that?
UPDATE ON Apoxio!!!!
OPAXIO Enrollment Milestone of 600 patient
Pivotal Registration Trial of OPAXIO Maintenance Therapy in First-Line Ovarian Cancer Reaches Enrollment Milestone of 600 patients, Cell Therapeutics and the Gynecologic Oncology Group Discuss Potential for Early Interim Analysis
CTI withdraws European Marketing Authorization Application (MAA) for non-inferiority indication in non-small cell lung cancer
SEATTLE, Sept. 21 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today that it will re-focus its resources on the approval of OPAXIO(TM) for its potential superiority indication in maintenance therapy for ovarian cancer. The Gynecologic Oncology Group (GOG) is conducting an ongoing phase III trial that evaluates the use of 12 months of OPAXIO therapy versus an untreated control arm. To date, 600 patients have been enrolled in this trial. CTI has discussed with the GOG, several strategies for conducting an interim analysis which could potentially result in an earlier registration. In addition, given the encouraging results of treatment of advanced esophageal cancer with OPAXIO to be reported at the upcoming International Society of Gastrointestinal Oncology Annual Meeting, CTI plans on meeting with the Food and Drug Administration (FDA) to discuss an additional registration study utilizing OPAXIO as a radiation sensitizer in the treatment of advanced esophageal cancer.
Related Quotes
Symbol Price Change
CTIC 1.13 +0.06
Chart for Cell Therapeutics, Inc.
{"s" : "ctic","k" : "c10,l10,p20,t10","o" : "","j" : ""}
CTI has notified the European Medicines Agency (EMEA) of its decision to withdraw its Marketing Authorization Application (MAA) for a non-inferiority indication in non-small cell lung cancer (NSCLC).
"Given that we have reached a milestone in the ovarian cancer trial enrollment coupled with the reservations the Committee for Medicinal Products for Human Use (CHMP) expressed about the control arm activity in the NSCL cancer study we believe it makes best sense for CTI to focus its efforts with OPAXIO on superiority applications like the first-line ovarian cancer trial as well as the exciting new potential application as a radiation sensitizer," noted Craig W. Philips, President of CTI. "Both of these studies would be landmark trials and first in class for this novel bioengineered taxane. We look forward to continuing to work with the GOG and ultimately the FDA on a registration pathway for OPAXIO."
"We believe focusing on ovarian maintenance, and radiosensitization, not only address areas of unmet medical need, but are in the best long term strategic interest of CTI. With the FDA review of the NDA for pixantrone in relapsed/refractory non-Hodgkin's lymphoma well underway and the phase III Ovarian trial of OPAXIO progressing nicely we are pleased with the advancement and future potential of these novel treatments," said James A. Bianco, M.D., CEO of CTI.
Where is the revenue reports? NEW YORK, Oct. 30, 2009 (GLOBE NEWSWIRE) -- Zevotek, Inc., (Pink Sheets:ZVTK - News) (Frankfurt:T5V1 - News), a worldwide direct marketer and distributor of innovative personal and home care items, announced today that an infomercial featuring Zevotek's Ionic Bulb will start airing in Europe next week. MediaShop AG, a direct marketer to nearly 100 million people in Germany, Switzerland and Austria, plans to launch their Ionic Bulb marketing campaign by airing a specially produced Ionic Bulb TV infomercial. Zevotek supplies the Ionic Bulbs that MediaShop plans to sell using their TV infomercial, www.mediashop.tv website and other promotions. Zevotek's Ionic Bulb is designed for consumer use by combining the performance features of ionic air cleaning technology with those of a 10,000 hour reduced energy use compact fluorescent light bulb (CFL). The Ionic Bulb is CE certified, signifying that the Ionic Bulb has met European Union (EU) consumer safety, health and environmental requirements.
When is the commercial supposed to air exactly?
Lol I cant find crap on this stock,lol thats good its a great kept secret!!!!
When are they supposed to dig? Lol This is going to be huge and its not any ones radar yet.lol So were looking pretty good if the volume stays moderately low. I'm thinking 20 dollars by middle next year!! Any one agree or disagree please post!!